Dapagliflozin reduces pulmonary vascular damage and susceptibility to atrial fibrillation in right heart disease
Release time:
1970-01-01
Dai C, Kong B, Shuai W, Xiao Z, Qin T, Fang J, Gong Y, Zhu J, Liu Q, Fu H, Meng H, Huang H. Dapagliflozin reduces pulmonary vascular damage and susceptibility to atrial fibrillation in right heart disease. ESC Heart Fail. 2023 Feb;10(1):578-593. doi: 10.1002/ehf2.14169. Epub 2022 Nov 11.
Activity Center